The lyme disease testing market size has grown strongly in recent years. It will grow from $10.68 billion in 2025 to $11.67 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to rising incidence of lyme disease, limited awareness about early diagnosis, reliance on conventional serological testing, increasing hospital-based diagnostics, growing research in tick-borne diseases.
The lyme disease testing market size is expected to see strong growth in the next few years. It will grow to $16.46 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to adoption of ai-assisted diagnostics, growth in home-testing kits, expansion of multi-disease panels, increasing government funding for tick-borne disease surveillance, integration of cloud-based laboratory data management. Major trends in the forecast period include point-of-care testing expansion, home-based lyme disease diagnostics, multi-pathogen tick-borne panels, rapid test kits adoption, personalized diagnostic protocols.
The increasing incidence of tick-borne diseases is anticipated to drive the expansion of the Lyme disease testing market in the coming years. Tick-borne diseases are a group of illnesses transmitted to humans through the bite of infected ticks, which are small, blood-feeding parasites commonly found in grassy, wooded, or rural regions. The growing need for treatments for tick-borne illnesses is driven by the widening geographic distribution of ticks due to climate change, resulting in greater exposure and higher infection rates. Tick-borne diseases fuel the demand for Lyme disease testing because they represent the primary route of Lyme disease transmission, making early detection and diagnosis essential for managing the increasing number of infection cases effectively. For example, in March 2025, the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency, reported that over 89,000 Lyme disease cases were recorded in 2023, indicating a persistently high burden of tick-borne illnesses compared to prior years. Thus, the growing prevalence of tick-borne diseases is contributing to the expansion of the Lyme disease testing market.
Companies in the Lyme disease testing market are emphasizing technological innovations in diagnostic tools to improve test accuracy, decrease turnaround times, and support early-stage disease detection. These diagnostic tools include devices, kits, and technologies designed to identify the presence of Lyme disease by detecting antibodies, antigens, or genetic material associated with Borrelia burgdorferi, the bacteria responsible for the disease. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, launched a new Lyme Disease Diagnostic Kit. This ELISA-based assay was developed using the company’s proprietary EpitoGen platform and includes approximately 120 distinct Borrelia epitopes, offering high specificity and sensitivity. Designed for research use only (RUO), the kit enables early, strain-specific detection and can be adapted for various laboratory settings, providing enhanced diagnostic accuracy and deeper insights into Lyme disease.
In May 2024, T2 Biosystems Inc., a US-based in vitro diagnostics company, formed a partnership with ECO Laboratory to improve early Lyme disease detection. This collaboration focuses on advancing the development and clinical validation of the T2Lyme Panel, a molecular diagnostic test aimed at providing accurate and early detection of Lyme disease. The partnership utilizes ECO Laboratory’s CLIA-certified facilities to broaden access to advanced tick-borne disease testing throughout the United States. ECO Laboratory is a US-based diagnostic service provider specializing in Lyme and other tick-borne illnesses.
Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.
North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lyme disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the Lyme disease testing market by increasing the cost of imported diagnostic reagents, laboratory equipment, and test kits, especially impacting nucleic acid tests and advanced serological assays. Regions such as North America and Europe, which rely on imported high-end testing equipment, face higher production costs and slower adoption rates. Hospitals, diagnostic laboratories, and research institutions are the most affected segments. On the positive side, tariffs are encouraging local manufacturing and development of cost-effective alternatives, which may reduce dependency on imports over time.
The lyme disease testing market research report is one of a series of new reports that provides lyme disease testing market statistics, including lyme disease testing industry global market size, regional shares, competitors with a lyme disease testing market share, detailed lyme disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the lyme disease testing industry. This lyme disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Lyme disease testing involves diagnostic methods used to identify infection with Borrelia burgdorferi, the bacterium responsible for Lyme disease, which is commonly transmitted via tick bites. The primary goal of Lyme disease testing is to ensure accurate diagnosis, particularly in individuals presenting symptoms such as fever, fatigue, and the distinctive bull's-eye rash.
The primary types of tests used in Lyme disease diagnostics include serological tests, nucleic acid tests, urine antigen tests, and others. Serological tests detect the presence of antibodies or antigens in a patient's blood to determine exposure to infections or immune responses. Common testing techniques include enzyme-linked immunosorbent assay (ELISA), Western blot, polymerase chain reaction (PCR), immunofluorescence assay (IFA), and others. Testing is applicable across different disease stages, including early Lyme disease, disseminated Lyme disease, chronic Lyme disease, and asymptomatic infection detection. Various sample types used include blood, urine, cerebrospinal fluid (CSF), and more. These diagnostic procedures are carried out by a range of end users, such as hospitals and clinics, diagnostic laboratories, home care settings, research institutions, and public health agencies.
The lyme disease testing market includes revenues earned by entities by providing services such as diagnostic test kit development, laboratory testing services, polymerase chain reaction (PCR)-based testing, serological testing, and point-of-care testing solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The lyme disease testing market size is expected to see strong growth in the next few years. It will grow to $16.46 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to adoption of ai-assisted diagnostics, growth in home-testing kits, expansion of multi-disease panels, increasing government funding for tick-borne disease surveillance, integration of cloud-based laboratory data management. Major trends in the forecast period include point-of-care testing expansion, home-based lyme disease diagnostics, multi-pathogen tick-borne panels, rapid test kits adoption, personalized diagnostic protocols.
The increasing incidence of tick-borne diseases is anticipated to drive the expansion of the Lyme disease testing market in the coming years. Tick-borne diseases are a group of illnesses transmitted to humans through the bite of infected ticks, which are small, blood-feeding parasites commonly found in grassy, wooded, or rural regions. The growing need for treatments for tick-borne illnesses is driven by the widening geographic distribution of ticks due to climate change, resulting in greater exposure and higher infection rates. Tick-borne diseases fuel the demand for Lyme disease testing because they represent the primary route of Lyme disease transmission, making early detection and diagnosis essential for managing the increasing number of infection cases effectively. For example, in March 2025, the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency, reported that over 89,000 Lyme disease cases were recorded in 2023, indicating a persistently high burden of tick-borne illnesses compared to prior years. Thus, the growing prevalence of tick-borne diseases is contributing to the expansion of the Lyme disease testing market.
Companies in the Lyme disease testing market are emphasizing technological innovations in diagnostic tools to improve test accuracy, decrease turnaround times, and support early-stage disease detection. These diagnostic tools include devices, kits, and technologies designed to identify the presence of Lyme disease by detecting antibodies, antigens, or genetic material associated with Borrelia burgdorferi, the bacteria responsible for the disease. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, launched a new Lyme Disease Diagnostic Kit. This ELISA-based assay was developed using the company’s proprietary EpitoGen platform and includes approximately 120 distinct Borrelia epitopes, offering high specificity and sensitivity. Designed for research use only (RUO), the kit enables early, strain-specific detection and can be adapted for various laboratory settings, providing enhanced diagnostic accuracy and deeper insights into Lyme disease.
In May 2024, T2 Biosystems Inc., a US-based in vitro diagnostics company, formed a partnership with ECO Laboratory to improve early Lyme disease detection. This collaboration focuses on advancing the development and clinical validation of the T2Lyme Panel, a molecular diagnostic test aimed at providing accurate and early detection of Lyme disease. The partnership utilizes ECO Laboratory’s CLIA-certified facilities to broaden access to advanced tick-borne disease testing throughout the United States. ECO Laboratory is a US-based diagnostic service provider specializing in Lyme and other tick-borne illnesses.
Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.
North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lyme disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the Lyme disease testing market by increasing the cost of imported diagnostic reagents, laboratory equipment, and test kits, especially impacting nucleic acid tests and advanced serological assays. Regions such as North America and Europe, which rely on imported high-end testing equipment, face higher production costs and slower adoption rates. Hospitals, diagnostic laboratories, and research institutions are the most affected segments. On the positive side, tariffs are encouraging local manufacturing and development of cost-effective alternatives, which may reduce dependency on imports over time.
The lyme disease testing market research report is one of a series of new reports that provides lyme disease testing market statistics, including lyme disease testing industry global market size, regional shares, competitors with a lyme disease testing market share, detailed lyme disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the lyme disease testing industry. This lyme disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Lyme disease testing involves diagnostic methods used to identify infection with Borrelia burgdorferi, the bacterium responsible for Lyme disease, which is commonly transmitted via tick bites. The primary goal of Lyme disease testing is to ensure accurate diagnosis, particularly in individuals presenting symptoms such as fever, fatigue, and the distinctive bull's-eye rash.
The primary types of tests used in Lyme disease diagnostics include serological tests, nucleic acid tests, urine antigen tests, and others. Serological tests detect the presence of antibodies or antigens in a patient's blood to determine exposure to infections or immune responses. Common testing techniques include enzyme-linked immunosorbent assay (ELISA), Western blot, polymerase chain reaction (PCR), immunofluorescence assay (IFA), and others. Testing is applicable across different disease stages, including early Lyme disease, disseminated Lyme disease, chronic Lyme disease, and asymptomatic infection detection. Various sample types used include blood, urine, cerebrospinal fluid (CSF), and more. These diagnostic procedures are carried out by a range of end users, such as hospitals and clinics, diagnostic laboratories, home care settings, research institutions, and public health agencies.
The lyme disease testing market includes revenues earned by entities by providing services such as diagnostic test kit development, laboratory testing services, polymerase chain reaction (PCR)-based testing, serological testing, and point-of-care testing solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Lyme Disease Testing Market Characteristics
3. Lyme Disease Testing Market Supply Chain Analysis
4. Global Lyme Disease Testing Market Trends and Strategies
5. Lyme Disease Testing Market Analysis of End Use Industries
7. Global Lyme Disease Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Lyme Disease Testing Total Addressable Market (TAM) Analysis for the Market
9. Lyme Disease Testing Market Segmentation
10. Lyme Disease Testing Market Regional and Country Analysis
11. Asia-Pacific Lyme Disease Testing Market
12. China Lyme Disease Testing Market
13. India Lyme Disease Testing Market
14. Japan Lyme Disease Testing Market
15. Australia Lyme Disease Testing Market
16. Indonesia Lyme Disease Testing Market
17. South Korea Lyme Disease Testing Market
18. Taiwan Lyme Disease Testing Market
19. South East Asia Lyme Disease Testing Market
20. Western Europe Lyme Disease Testing Market
21. UK Lyme Disease Testing Market
22. Germany Lyme Disease Testing Market
23. France Lyme Disease Testing Market
24. Italy Lyme Disease Testing Market
25. Spain Lyme Disease Testing Market
26. Eastern Europe Lyme Disease Testing Market
27. Russia Lyme Disease Testing Market
28. North America Lyme Disease Testing Market
29. USA Lyme Disease Testing Market
30. Canada Lyme Disease Testing Market
31. South America Lyme Disease Testing Market
32. Brazil Lyme Disease Testing Market
33. Middle East Lyme Disease Testing Market
34. Africa Lyme Disease Testing Market
36. Lyme Disease Testing Market Competitive Landscape and Company Profiles
37. Lyme Disease Testing Market Other Major and Innovative Companies
40. Lyme Disease Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Lyme Disease Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses lyme disease testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for lyme disease testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lyme disease testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Serological Tests; Nucleic Acid Tests; Urine Antigen Tests; Other Test Types2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA); Weste Blot; Polymerase Chain Reaction (PCR); Immunofluorescence Assay (IFA); Other Emerging Technologies
3) By Disease Stage: Early Lyme Disease; Disseminated Lyme Disease; Chronic Lyme Disease; Asymptomatic Lyme Disease Detection
4) By Sample Type: Blood; Urine; Cerebrospinal Fluid(CSF); Other Blood Samples
5) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Home Care Settings; Research Institutions; Public Health Organizations
Subsegments:
1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)
3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests
4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools
Companies Mentioned: Roche Holding AG; Thermo Fisher Scientific Inc.; Labcorp Holdings Inc.; Quest Diagnostics Incorporated; Eurofins Scientific; BIOMÉRIEUX; Quidel Corporation; Bio Rad Laboratories Inc.; QIAGEN N.V.; DiaSorin S.p.A; Meridian Bioscience; Trinity Biotech; T2 Biosystems; IGeneX; Viramed Biotech AG; Ceres Nanosciences; Galaxy Diagnostics; Lyme Diagnostics Ltd; Abbott Laboratories; Siemens Healthineers AG; Hologic Inc.; Seegene Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Lyme Disease Testing market report include:- Roche Holding AG
- Thermo Fisher Scientific Inc.
- Labcorp Holdings Inc.
- Quest Diagnostics Incorporated
- Eurofins Scientific
- BIOMÉRIEUX
- Quidel Corporation
- Bio Rad Laboratories Inc.
- QIAGEN N.V.
- DiaSorin S.p.A
- Meridian Bioscience
- Trinity Biotech
- T2 Biosystems
- IGeneX
- Viramed Biotech AG
- Ceres Nanosciences
- Galaxy Diagnostics
- Lyme Diagnostics Ltd
- Abbott Laboratories
- Siemens Healthineers AG
- Hologic Inc.
- Seegene Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.67 Billion |
| Forecasted Market Value ( USD | $ 16.46 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
